National academy

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

Retrieved on: 
Friday, August 13, 2021
Forward-looking statement, Intussusception (medical disorder), Clinical trial, Muscle, ADL, Calendar, Observation, HLHS, CGMP, NIA, Emax, Safety, Pros, National Institute on Aging, Company, SBIR, Risk, SEC, Miami, Telephone, FDA, Fear, Cognition, Particle-size distribution, Depression, Weight loss, Inflammation, Infection, Population, Adult, Walking, CEO, Microsoft, Goal, Patent, Intention, Cell, Small Business Innovation Research, Fatigue, Conference, Metabolic syndrome, Bone marrow, National academy, Malnutrition, Physician, International Conference on the Holocaust and Genocide, Hospital, NASDAQ, Terminology, Serum, Hypoplastic left heart syndrome, Disorder, National Academy of Medicine, Linearity, National Institute, Education, Program, Immune system, GLOBE, CHSA, Medical imaging, Pharmaceutical industry, Fertilizer

MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced results from the Company’s Phase 2b trial titled: A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B Infusion in Patients With Aging Frailty (the “Phase 2b trial”). Lomecel-B is a proprietary allogeneic product comprised of medicinal signaling cells (MSCs) from the bone marrow of adult donors and culture-expanded in Longeveron’s current good manufacturing practice (cGMP) cell processing facility. The Phase 2b trial, which was partially funded by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), evaluated the safety and efficacy of a single peripheral intravenous infusion of four different doses of Lomecel-B cell therapy (25 million (n=37), 50 million (n=31), 100 million (n=34) and 200 million (n=16) cells; sample size reflects any subject that was randomized and received an infusion) compared to placebo (n=30), on signs and symptoms of Aging Frailty, including mobility and exercise tolerance.

Key Points: 
  • About the US Phase 2b Aging Frailty Trial:
    The primary objective of this multi-center study is to assess the effect of Lomecel-B on exercise tolerance and endurance via the six-minute walk test (6MWT).
  • Aging Frailty is a life-threatening geriatric condition affecting approximately 15% of Americans over the age of 65, or 8.1 million individuals.
  • The necessity for identifying patients with Aging Frailty is well-acknowledged in the geriatric community, and the treatment of Aging Frailty and promotion of healthful aging are recognized priorities of the National Academy of Medicine and NIA/NIH.
  • Despite the pressing need for interventions, there are no FDA-approved therapies that can slow down, reverse, or prevent Aging Frailty.

Intel Appoints Christy Pambianchi as Executive Vice President and Chief People Officer

Retrieved on: 
Wednesday, August 11, 2021
Other Manufacturing, Technology, Semiconductor, Software, Manufacturing, Networks, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, People, Intelligence, Industry, Policy, Human resources, Association, FTC, INTC, Intel, Technology, Time, Cornell University School of Industrial and Labor Relations, Christy, Cornell University, University, Lumina Foundation, Semiconductor, Learning, National academy, School, Digital, FIRST, PepsiCo, Multimedia, Corning Inc., Nasdaq, Verizon Communications, Center, Cornell University Center for Advanced Computing, Culture, Name, Management

Intel Corporation today announced the appointment of Christy Pambianchi as executive vice president and chief people officer, effective Sept. 7.

Key Points: 
  • Intel Corporation today announced the appointment of Christy Pambianchi as executive vice president and chief people officer, effective Sept. 7.
  • View the full release here: https://www.businesswire.com/news/home/20210811005632/en/
    Christy Pambianchi joins Intel Corporation in September 2021 as executive vice president and chief people officer.
  • Pambianchi was formerly executive vice president of People & Digital at Corning Inc., where she served in various senior leadership roles during a 20-year tenure.
  • Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

Independent Sector Names Recipients of 2021 John W. Gardner Leadership Award

Retrieved on: 
Wednesday, August 11, 2021
Well, Trust, Board for International Food and Agricultural Development (BIFAD), Summit, WKKF, Life, CEO, Council of Senior Scholars (Saudi Arabia), Senior advisor, Foundation, Democracy, Alternative, Book, Time, The Washington Campus Board of Directors, National Academy of Public Administration (United States), Spirituality, National Collaborating Centre for Infectious Diseases, George Mason University, Berkeley, National academy, Policy, Institute, Man, Transformation, Movement, Social justice, Goal, Justice, University, Board, PolicyLink, Social change, McAfee, Leadership, Connective tissue, Center, Government, GLOBE, Poverty, Independent Sector, Woman, Health equity, Management

Washington, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dr. Gail C. Christopher and Professor john a. powell have been named the recipients of Independent Sectors 2021 John W. Gardner Leadership Award.

Key Points: 
  • Washington, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dr. Gail C. Christopher and Professor john a. powell have been named the recipients of Independent Sectors 2021 John W. Gardner Leadership Award.
  • Since 1985, Independent Sector has presented the John W. Gardner Leadership Award annually to visionaries who exemplify the leadership and ideals of John W. Gardner (1912-2002), American statesman, educator, author, and IS founder.
  • We could not be more pleased to honor both Dr. Christopher and Professor powell with the 2021 John W. Gardner Leadership Award.
  • Im honored to join Dr. Gail Christopher as one of the two recipients of Independent Sectors 2021 John W. Gardner Leadership Award, as well as being associated with the incredible honorees of the past, said Professor john a. powell.

Emmaus Life Sciences Provides SEC Reporting Update

Retrieved on: 
Tuesday, August 10, 2021
Extremities, Chest pain, Income, Headache, Incidence, Safety, End organ damage, Sickle, Patient, Splenomegaly, Science, Annual report, Pain, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Center, Disability in Canada, Security (finance), Blueprint, African Americans, Time, OTC, Hispanic and Latino Americans, Q1, Sale, National academy, Back pain, Adult, Sickle cell disease, Birth, Nausea, Mission statement, Indigestion, Indication, Cough, OTC Markets Group, SEC, Constipation, Abdominal pain, Marketing, Form 10-K, SCD, Blood, Centers for Disease Control and Prevention, Form, Pharmaceutical industry, Vaccine

TORRANCE, Calif., Aug. 10, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the fiscal year ended December 31, 2020, and that investors should no longer rely upon the financial statements included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on May 4, 2021. Similarly, any earnings releases and other press releases and investor communications containing information derived from such financial statements should no longer be relied upon. Emmaus also provided an update on the filing of its delinquent quarterly reports.

Key Points: 
  • The restated 2020 financial statements are set forth in Emmaus' amended and restated Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020, filed with the SEC today.
  • The Form 10-K/A also contains a currently dated, unqualified audit report of Emmaus' independent public accounting firm on the restated financial statements.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.
  • 2 Source: Committee on Addressing Sickle Cell Disease A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

International Fitness Academy Partners with Precision Nutrition to Bring Industry-Leading Nutrition and Change Psychology Courses, Certifications, and Software to Asia-Pacific Countries

Retrieved on: 
Tuesday, August 10, 2021
Chartered Institute for the Management of Sport and Physical Activity, Software, Business development, Nutrition, Health, VP, COVID-19, GLOBE, National academy, National Board of Physician Nutrition Specialists, CECS, Wellness, IFA, Industry, Sports medicine, Science, Physical activity, Partnership, American College of Sports Medicine, United Arab Emirates, Face, Learning, ACE, NASM, Certification, ACSM, Advance Certificate of Secondary Education Examination (Tanzania), American College, List of professional associations in the United Kingdom, PN, National Academy of Sports Medicine, Acceleration, Physiology, Student, Man, Education, Goal, Psychology, American Council, Medicine, Tutoring

Through the partnership, IFA will be offering PNs full suite of nutrition, change psychology, and health certificates, courses, and software to students and graduates of IFAs training fitness education program.

Key Points: 
  • Through the partnership, IFA will be offering PNs full suite of nutrition, change psychology, and health certificates, courses, and software to students and graduates of IFAs training fitness education program.
  • Our partnership with Precision Nutrition is about breaking boundaries in online learning and creating exciting opportunities for the next generation of fitness coaches.
  • PN Level 1 Nutrition Certification: the worlds number one recommended nutrition certificationtrusted by more than 150,000 health and fitness professionals in over 50 countries.
  • As a leading global education provider, International Fitness Academy (IFA) is reshaping and rethinking the fitness and wellness industry now and for future generations.

Innovent Announces the Establishment of the Scientific Advisory Board

Retrieved on: 
Monday, August 9, 2021
NMPA, Environment, National academy, Eli Lilly and Company, Metabolism, Bevacizumab, HKEX, American Academy, Control, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Coronavirus Scientific Advisory Board (Turkey), SAN, Biologics license application, NDA, Cancer, Science, BLA, CMC, San Francisco, University, MD Anderson Cancer Center, News, Review, Social conditions in Honduras, Patient, Chemistry, Immunology, Sanofi, Autoimmunity, Stock exchange, Integrity, Marketing, SAB, Motherboard, Research, Novartis, Drug discovery, Sintilimab, Nature, American Cancer Society, Company, Pharmaceutical industry, Management, Fine chemical

SAN FRANCISCOand SUZHOU,China, Aug. 8, 2021 /PRNewswire/ --Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceuticalcompany that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,announces today the establishment of Scientific Advisory Board (SAB).

Key Points: 
  • SAN FRANCISCOand SUZHOU,China, Aug. 8, 2021 /PRNewswire/ --Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceuticalcompany that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,announces today the establishment of Scientific Advisory Board (SAB).
  • The SAB is to provide scientific advices to our research and clinical pipelines that fulfills the mission and vision of Innovent along with the global reach to benefit patients worldwide.
  • Dr. Carlos Garcia-Echeverria, an accomplished drug discovery scientist and pharma executive, bringing 25+ years experiences from EQRx, Sanofi and Novartis.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 5, 2021
Science, Toxicity, Drug discovery, SAN, Antibody, Neoplasm, Transferrin receptor 1, Safety, LinkedIn, Â, Clinical trial, Amgen, National, ALCAM, Twitter, Bristol Myers Squibb, Food and Drug Administration, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Interest, Therapy, Risk, CD137, United, IND, Tumor microenvironment, Clinical Cancer Research, Food, GLOBE, AbbVie, Investment, Webcast, Breast cancer, Journal, ADC, Program, Patient, COVID-19, Ipilimumab, Triple-negative breast cancer, B-cell lymphoma, Nasdaq, Immunotherapy, Biotechnology, Head, National academy, Nivolumab, International, Pharmaceutical industry, Tutoring, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today reported second quarter 2021 financial results and provided a business update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today reported second quarter 2021 financial results and provided a business update.
  • In the second quarter of 2021, we continued to advance our broad pipeline of Probody therapeutics across multiple modalities and cancer types.
  • Initial data from this study is anticipated in the fourth quarter of 2021.
  • CytomX will continue to discuss the program with Amgen and is working toward the filing of an IND in late 2021.

FOX News Channel Names Jacqui Heinrich White House Correspondent and Aishah Hasnie Congressional Correspondent

Retrieved on: 
Thursday, August 5, 2021
Entertainment, Other Entertainment, TV and Radio, General Entertainment, Celebrity, Mobile Entertainment, Licensing (Entertainment), 48th Daytime Emmy Awards, KYW-TV, Geo TV, Industry, Suffolk University, Society, Heinrich, Mental health, Science, Fox, Nursing, International relations, George Washington University School of Media and Public Affairs, Islam in the United States, Quinnipiac University, KTNV-TV, News, FNC, Hurricane Sally, Democrat, Journalism, WHTM-TV, Nexstar Media Group, Congress, Legislation, Republican National Convention, Fox News, Mid-Atlantic Emmy Awards, Mississippi Gulf Coast, 4, Capitol Hill, CBS, 1952 Democratic National Convention, White, Coronavirus, Voyeurism, Television, NBC, Academy of Television Arts & Sciences Foundation, WXIN, Democratic National Convention, COVID-19, ABC, WFXT, CBS 3, Heart, White House, Death, National academy, Animal, Auction

FOX News Channel (FNC) has named Jacqui Heinrich White House correspondent, announced Jay Wallace, president and executive editor of FOX News Media.

Key Points: 
  • FOX News Channel (FNC) has named Jacqui Heinrich White House correspondent, announced Jay Wallace, president and executive editor of FOX News Media.
  • She will report alongside FNCs Peter Doocy, who will continue in his role as White House correspondent for the network.
  • Additionally, Aishah Hasnie has been promoted to Congressional correspondent beginning in mid-August, while Alexandria Hoff will join FNC as a Washington based general assignment reporter in early September.
  • Most recently, Heinrich served as Congressional correspondent for FNC in Washington, DC.

Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors

Retrieved on: 
Thursday, August 5, 2021
GlaxoSmithKline, Infection, Optimism, Vaccine, Industry, Academy of Medical Sciences (United Kingdom), University, Technology, Science, Division, Takeda, Academy, Virus, Medicine, University of Washington Department of Global Health, Severe acute respiratory syndrome coronavirus 2, VLP, Health, Board, RSV, GLOBE, News, Leadership, Department, Â, Human, Public health, Bill, Institute, Internal medicine, National Academy of Medicine, Family, Friends, National academy, Pharmaceutical industry

It is with great sadness that we share the news of our Chairman and co-founders sudden passing.

Key Points: 
  • It is with great sadness that we share the news of our Chairman and co-founders sudden passing.
  • Tachi was a brilliant man, a physician-scientist, and deeply committed to the cause of public health, said Adam Simpson, Chief Executive Officer of Icosavax, Inc.
  • I had the honor not just of co-founding Icosavax with Tachi, but working with him previously.
  • Needless to say, the Board, leadership, and employees of Icosavax offer their heartfelt condolences to Tachis family and friends at this time.

Anthem’s Board Welcomes Susan Dodson DeVore as New Director

Retrieved on: 
Wednesday, August 4, 2021
General Health, Health, Professional Services, Insurance, Managed Care, People, Company, Ernst & Young, Efficiency, Solution, Woman, Healthcare Leadership Council, Technology, Partner, Unum, Health, Twitter, Board, Leadership, Premier, Inc., Science, Ernst, New York Stock Exchange, Hospital, Board of directors, National academy, ANTM, Modern Healthcare, Management

The Board of Directors of Anthem, Inc. (NYSE: ANTM) announced that Susan Dodson DeVore has joined the Board.

Key Points: 
  • The Board of Directors of Anthem, Inc. (NYSE: ANTM) announced that Susan Dodson DeVore has joined the Board.
  • Ms. DeVore also has over twenty years of finance, strategy and healthcare consulting experience, including as Partner and Region Leader for the Health Care Consulting Practice at Ernst & Young.
  • Ms. DeVore currently serves on the board of UNUM Group and previously chaired the Healthcare Leadership Council and co-chaired the National Academy of Medicines Value and Science Driven Health Care Collaborative.
  • We are pleased to welcome Susan to our Board of Directors, said Elizabeth Tallett, Chair, Anthem Board of Directors.